Quick Answer
Hepion Pharmaceuticals, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2023.
Hepion Pharmaceuticals, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2023 | $0.00 | — |
| 2022 | $0.00 | — |
| 2021 | $0.00 | — |
| 2020 | $0.00 | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| March 31, 2024 | $0.00 | — | — |
| September 30, 2023 | $0.00 | — | — |
| June 30, 2023 | $0.00 | — | — |
| March 31, 2023 | $0.00 | — | — |
| September 30, 2022 | $0.00 | — | — |
| June 30, 2022 | $0.00 | — | — |
| March 31, 2022 | $0.00 | — | — |
| September 30, 2021 | $0.00 | — | — |
- The most recent figure is from Hepion Pharmaceuticals, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on April 16, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: